Do dopamine agonists provide neuroprotection?

Neurology

Volumn 51, Issue 2 SUPPL., 1998, Pages

  Yamamoto, Mitsutoshi ^a  

^a KAGAWA PREFECTURAL CENTRAL HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BROMOCRIPTINE; DOPAMINE RECEPTOR STIMULATING AGENT; LISURIDE; PERGOLIDE;

CONFERENCE PAPER; DRUG ACTIVITY; DRUG EFFECT; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; NEUROPROTECTION; OXIDATIVE STRESS; PARKINSON DISEASE; PRIORITY JOURNAL;

EID: 0031688694     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/wnl.51.2_suppl_2.s10     Document Type: Conference Paper

References (33)

1. Felten DL, Felten SY, Fuller RW, et al. Chronic dietary pergolide preserves nigrostriatal neuronal integrity in aged-Fisher-344 rats. Neurobiol Aging 1992;13:339-351.
2. Ogawa N, Tanaka K, Asanuma M, et al. Bromocriptine protects mice against 6-hydroxydopamine and scavenges hydroxyl free radicals in vitro. Brain Res 1994;657:207-213.
3. Yoshikawa T, Minamiyama Y, Naito Y, Kondo M. Antioxidant properties of bromocriptine, a dopamine agonist. J Neurochem 1994;62:1034-1038.
4. Carter AJ, Muller RE. Pramipexole, a dopamine D2 receptor agonist, decreases the extracellular concentration of dopamine in vivo. Eur J Pharmacol 1991;200:65-72.
5. Hall E, Andrus P, Oostveen J, Althaus JS, Von Voitlander PF. Neuroprotective effects of the dopamine D2/D3 agonist pramipexole agonist postischemic or amphetamine-induced degeneration of nigrostriatal neurons. Brain Res 1996;742: 80-88.
6. Sethy VH, Wu H, Oostveen J, Hall E. Neuroprotective effects of the dopamine agonist pramipexole and bromocriptine in 3-acetylpyridine-treated rats. Brain Res 1997;754: 181-186.
7. Lieberman A. Dopamine agonists used as monotherapy in de novo PD patients: comparisons with selegiline. Neurology 1992;42(Suppl 4):37-40.
8. Olanow CW. Attempts to obtain neuroprotection in Parkinson's disease. Neurology 1997;49(Suppl 1):S26-33.
9. Parkinson's Study Group. Effects of deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med 1989;321:1364-1371.
10. Parkinson's Study Group. Effects of tocopherol and deprenyl on the progression of disability in Parkinson's disease. N Engl J Med 1993;328:176-183.
11. Schulzer M, Mak E, Calne DB. The antiparkinson efficacy of deprenyl derives from transient improvement that is likely to be symptomatic. Ann Neurol 1992;32:795-798.
12. Fowler JS, Fazzini DO, Volkow ND. Deprenyl and levodopa and Parkinson's disease progression. Ann Neurol 1966;40: 267-268.
13. Graham DC, Tiffany SM, Bell WE Jr, Gutknecht WF. Autooxidation versus covalent binding of quinones as the mechanism of toxicity of dopamine, 6-hydroxydopamine, and related compounds toward C1300 neuroblastoma cells in vitro. Mol Pharmacol 1978;14:644-653.
14. Olanow CW. An introduction to the free radical hypothesis in Parkinson's disease. Ann Neurol 1992;32:S2-9.
15. Fahn S, Cohen G. The oxidant stress hypothesis in Parkinson's disease: evidence supporting it. Ann Neurol 1992;32: 804-812.
16. Calne DB. The free radical hypothesis in idiopathic parkinsonism: evidence against it. Ann Neurol 1992;32:799-803.
17. Fahn S. Controversies in the therapy of Parkinson's disease. Adv Neurol 1996;69:477-485.
18. Sofic E, Lange KE, Jellinger K, Riederer P. Reduced and oxidized gluthathione in the substantia nigra of patients with Parkinson's disease. Neurosci Lett 1992;142:128-130.
19. Shian J, Dexter DT, Lees AJ, et al. Alterations in glutathione levels in Parkinson's disease and other neurodegenerative disorders affecting basal ganglia. Ann Neurol 1994;36: 348-355.
20. Schapira AHV, Cooper JM, Dexter D, et al. Mitochondrial complex I deficiency in Parkinson's disease. Lancet 1989;1: 1269.
21. Mann VM, Cooper JM, Krige D, et al. Brain, skeletal muscle and platelet mitochondrial function in Parkinson's disease. Brain 1992;115:333-342.
22. Martilla RJ, Lorentz H, Rinne UK. Oxygen toxicity protecting enzymes in Parkinson's disease. Increase of superoxide dismutase-like activity in the substantia nigra and basal ganglia. J Neurol Sci 1988;86:321-331.
23. Saggu H, Cooksey J, Dexter DT, et al. A selective increase in particulate superoxide dismutase activity in parkinsonian substantia nigra. J Neurochem 1989;53:693-697.
24. Riederer P, Sofic E, Rausch WD, et al. Transition metals, ferratin, glutathione, and ascorbic acid in parkinsonian brains. J Neurochem 1989;52:515-520.
25. Watts RL. The role of dopamine agonists in early Parkinson's disease. Neurology 1997;49(Suppl 1):S34-48.
26. Fabrini G. Motor fluctuations in Parkinson's disease-central pathophysiological mechanism, part 1. Ann Neurol 1988;24: 366-371.
27. Rinne UK. Dopamine agonists as primary treatment in Parkinson's disease. Adv Neurol 1986;45:519-523.
28. Ogawa N, Kanazawa I, Kowa H, et al. Nationwide multicenter prospective study on the long-term effects of bromocriptine for Parkinson's disease: final report of a ten year follow-up. Eur Neurol 1997;38(Suppl 2):37-49.
29. Weiner WJ, Factor SA, Sanchez-Ramos JR, et al. Early combination therapy (bromocriptine) does not prevent motor fluctuations in Parkinson's disease. Neurology 1989;43:21-26.
30. Lees AJ, Stern G. Sustained bromocriptine therapy in previously untreated patients with Parkinson's disease. J Neurol Neurosurg Psychiatry 1981;44:1020-1023.
31. Bergamasco B, Benna P, Scarzalla L. Long-term bromocriptine treatment of de novo patients with Parkinson's disease. A seven-year follow-up. Acta Neurol Scand 1990;81:383-387.
32. Mizuno Y, Kondo T, Narabayashi H. Pergolide in the treatment of Parkinson's disease. Neurology 1995;45(Suppl 3):S13-21.
33. Marttila RJ, Rinne UK. Disability and progression in parkinsonism. Acta Neurol Scand 1977;56:159-169.